Table 5: The frequency of adverse events mild to moderate grades from day 1 to day 42 (related or not) after treatment initiation.
| Symptoms (N(%)) |
AL (N = 72) |
ASMF (N = 0.72) |
DHAP (N = 0.72) |
P |
|
|
(1) (2) |
|||||
|
Weakness/Fatigue |
13 (18.0) |
14 (19.4) |
8 (11.1) |
0.008 |
0.01 |
|
Loss of appetite |
12 (16.7) |
14 (19.4.0) |
4 (5.5) |
0.013 |
0.016 |
|
Pruritus |
10 (13.9) |
11 (15.3) |
2 (2.8) |
0.013 |
0.0144 |
|
Headache |
2 (2.8) |
9 (12.5) |
0 |
0.003 |
0.014 |
|
Dizziness |
0 |
4 (5.5) |
0 |
0.0064 |
|
|
Abdominal pain |
13 (18.0) |
17 (23.6) |
4 (5.5) |
0.015 |
0.021 |
|
Vomiting |
8 (11.1) |
15 (20.8) |
3 (4.2) |
0.01 |
0.02 |
|
Diarrhea |
5 (6.9) |
4 (5.5) |
5 (6.9) |
0.002 |
|
|
Cough |
45 (62.5) |
34 (47.2) |
35 (48.6) |
0.016 |
0.016 |
|
Skin rash |
8 (11.1) |
6 (8.3) |
2 (2.8) |
0.006 |
0.006 |
|
Hallucination |
0 |
2 (2.8) |
0 |
0.0032 |
|
|
Insomnia |
3 (4.2) |
11 (15.3) |
1 (1.4) |
0.0032 |
0.016 |
P value; (1) Compare DHAP vs. AL; (2) Compare DHAP vs. ASMF.